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Abstract
Background: Staphylococcus aureus and Pseudomonas aeruginosa are major causes of pneumonia in intensive
care unit (ICU) patients. Limited data exist regarding the health economic impact of S. aureus and P. aeruginosa
pneumonias in the ICU setting.
Methods: We conducted a retrospective observational cohort study using a 29.6 million enrollee US medical and
pharmacy administrative claims database. ICU patients with S. aureus or P. aeruginosa infection per International
Classification of Diseases, 9th ed. coding between 01/01/2007-8/31/2012 were compared with ICU patients without any
pneumonia or infections of interest. Primary outcomes were costs in 2012 US dollars, healthcare utilization and
all-cause mortality associated with hospital-acquired S. aureus or P. aeruginosa pneumonia, and the relative odds
of incurring higher costs due to a comorbid condition.
Results: Patients with S. aureus or P. aeruginosa pneumonia had longer mean hospital (37.9 or 55.4 vs 7.2 days,
P < .001) and ICU stays (6.9 or 14.8 vs 1.1 days, P < .001), a higher rate of mechanical ventilation (62.6 % or 62.3 %
vs 7.4 %, P < .001), higher mortality (16.0 % or 20.2 % vs 3.1 %, P < .001), and higher total mean hospitalization
costs ($146,978 or $213,104 vs $33,851, P < .001) vs controls. Pneumonia survivors had significantly increased
risk of rehospitalization within 30 days (27.2 % or 31.1 % vs 15.3 %, P < .001). Comorbid conditions were not
associated with increased cost in the pneumonia cohorts.
Conclusions: Healthcare costs and resource utilization were high among ICU patients with S. aureus or P.
aeruginosa pneumonia. Reducing the incidence of these infections could lead to substantial cost savings in
the United States.
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Background
Staphylococcus aureus (S. aureus) and Pseudomonas
aeruginosa (P. aeruginosa) are responsible for much of
the hospital-acquired pneumonia in the United States,
accounting for approximately 28 %-47%and 18 % of
hospitalizations, respectively [1, 2]. Despite preventive
strategies, ventilator-associated pneumonia (VAP) re-
mains the most frequent infection occurring in ICU pa-
tients [3]. S. aureus and P. aeruginosa cause 20 %-31 %
and 21 %-24 % of VAP, [4–6] and 14 % and 13 % of
non-VAP in intensive care unit (ICU) patients, respect-
ively, in the United States [4]. These infections are as-
sociated with excess costs, lengths of stay, and
mortality rates [2, 7–11]. Furthermore, infections due
to antibiotic-resistant strains of S. aureus [6, 12, 13]
and P. aeruginosa [14–18] add considerable disease
burden and are associated with significantly higher
costs, lengths of stay, and mortality versus infections
caused by antibiotic-susceptible strains.
Limited data exist regarding the pharmacoeconomic
and health outcomes of S. aureus and P. aeruginosa
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pneumonias in the ICU setting. This study assesses the
impact of S. aureus or P. aeruginosa pneumonia in ICU
patients on healthcare costs, utilization, and mortality




This retrospective observational cohort study of admin-
istrative claims data from the HealthCore Integrated Re-
search Environment for service dates from 01/01/2006
through 11/30/2012 was developed to assess costs and
outcomes of S. aureus and P. aeruginosa pneumonia in
ICU patients to guide the development of monoclonal
antibodies designed to prevent these illnesses [19, 20].
The HealthCore database contains longitudinal claims
data from one of the largest commercially insured popu-
lation in the United States, including approximately 29.6
million enrollees in commercial health plans at the time
of this study. On average, the population included in the
HealthCore database has a higher household income, a
lower proportion of individuals older than 65 years, and
a higher proportion of whites compared to the overall
US population. The observational and longitudinal aspects
of the retrospective cohort design facilitated simultaneous
capture of prior and follow-up data relative to the index
event. The study was conducted in compliance with US
federal regulations, the Health Insurance Portability and
Accountability Act, and the Helsinki Declaration. Patient-
specific data was de-identified, therefore, informed con-
sent and institutional review board or ethics committee
approval were not required for this study.
Study population
The eligible population comprised patients with ≥1 in-
patient hospitalization that included an ICU stay and an
admission and discharge between 01/01/2007 and 08/31/
2012 (Fig. 1). Admissions to medical, surgical, cardiac,
Fig. 1 Inclusion/exclusion criteria, cohort definition, and patient counts. Cohort 1: Controls (no pneumonia); excluded the following conditions
and Cohort 2 and Cohort 3: Viral pneumonia (ICD-9 dx 480.xx); Other pneumonia with specified bacteria: Pneumococcal pneumonia (481.xx),
Other specified bacterial pneumonia (482.0x, 482.2x, 482.3x, 482.8x), Bronchopneumonia (485.xx); Pneumonia due to unspecified bacteria: Unspecified
bacterial pneumonia (482.9x), Pneumonia, organism unspecified [bacterial or viral] (486.xx), Ventilator associated pneumonia (VAP) (997.31); Other
pneumonias: Aspiration Pneumonia (507.0x), Post-procedural pneumonia (997.32); Septicemia due to staphylococcus or pseudomonas: Staphylococcal
septicemia, unspecified (038.10), Methicillin susceptible Staphylococcus aureus septicemia (038.11), Methicillin resistant Staphylococcus aureus
septicemia (038.12), Septicemia due to pseudomonas (038.43); Other bacterial infections due to staphylococcus or pseudomonas: Staphylococcus,
unspecified (041.10), Methicillin susceptible Staphylococcus aureus (041.11), Methicillin resistant Staphylococcus aureus (041.12), Pseudomonas (041.7);
Staphylococcal meningitis (320.3x); Bacteremia (790.7x). Cohort 2: Pneumonia due to staphylococcus (ICD-9 diagnosis: 482.4x). Cohort 3: Pneumonia
due to pseudomonas (ICD-9 diagnosis: 482.1x). Cohort 2 and Cohort 3 are not necessarily mutually exclusive. Patients with diagnosis codes
for both pneumonia due to staphylococcus and pneumonia due to pseudomonas during the index hospitalization visit are included in both
cohorts (N = 132)
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pediatric (including neonatal) ICUs were included. The
first inpatient hospitalization that included any stay in an
ICU was defined as the index hospitalization. To permit
the identification of comorbid conditions and to assess
long-term outcomes, eligible patients had ≥1 year of
health plan enrollment before the admission date with
continuous enrollment during the inpatient episode and
≥90 days of enrollment following the discharge date
(unless death occurred first). Patients diagnosed with
pneumonia within 30 days and patients diagnosed with
cystic fibrosis within 12 months before the index period
were excluded. The observation period for each patient
was divided into pre-index, index, and 2 post-index
time intervals. These were defined, respectively, as the
12 months before the index hospitalization, the index
hospitalization itself, and both 30- and 90-day follow up
periods post discharge from the index hospitalization.
Eligible ICU patients were divided into 3 primary groups
based on International Classification of Disease Clinical
Modification, Ninth revision (ICD-9) diagnosis codes: pa-
tients not diagnosed with pneumonia (Cohort 1–controls),
patients with S. aureus pneumonia (Cohort 2), and pa-
tients with P. aeruginosa pneumonia (Cohort 3) (Fig. 1).
Both primary and secondary diagnosis codes for the index
hospitalizationwere used to assign subjects into groups.
Outcomes
The main study outcomes included the total healthcare
cost of the index hospitalization, the total length of stay,
all-cause mortality during the index hospitalization, and
the relative odds if the presence of a comorbid condition
would result in higher total index hospitalization cost.
The study also examined mechanical ventilation and
ICU length of stay during the index hospitalization, and
all-cause healthcare costs, all-cause mortality, hospital
readmission, hospital and ICU lengths of stay, and anti-
biotic use during the post-index periods.
A comorbid condition was defined as the presence of ≥1
medical claim with a diagnosis code for the condition of
interest for an individual during the 12 months prior to
the index hospitalization. The total cost of care, including
costs paid by the patient and those paid by the health plan,
are included in all cost calculations. Post-index costs are
reported as those incurred during inpatient hospitaliza-
tions (inpatient costs) as well as costs incurred in all places
of service (total all-cause costs). Antibiotic use was cap-
tured via pharmacy and medical claims. The administra-
tive claims data were linked to the Social Security Death
Index to capture mortality during the post-index period.
Analysis
Statistical analyses of the S. aureus and P. aeruginosa
cohorts were performed separately against the control
cohort. Cost outcomes were analyzed using a generalized
linear model with gamma distribution and a log link func-
tion. Unadjusted differences in mean costs were reported
for pre- and post-index periods, while means adjusted for
covariates were reported for the primary outcome of index
costs. Covariates for adjusted cost models included age
(continuously), gender, health plan type, geographic re-
gion, Deyo-Charlson comorbidity index score (DCI), [21]
and the analogous pre-index cost for index and post-index
cost analyses only (index and post-index hospitalization
cost models adjusted for pre-index hospitalization costs,
total all-cause post-index costs adjusted for total pre-
index costs).
Count variables and lengths of stay were analyzed using
a generalized linear model with a negative binomial distri-
bution with a log link function. Differences in index
hospitalization length of stay were adjusted for the same
covariates listed above, while unadjusted mean differences
are reported for all pre- and post-index models. Logistic
regression was used to analyze dichotomous variables with
results reported as unadjusted odds ratios. Survival rates
were calculated using Kaplan-Meier analysis, and un-
adjusted Cox-proportional hazards were used to analyze
differences in survival between cohorts. The association
between comorbid conditions and index hospitalization
cost was analyzed separately within each cohort by divid-
ing each cohort into quintiles of index hospitalization cost
and calculating the prevalence of each comorbid condition
within each quintile. Ordinal logistic regression was used
to determine whether each comorbid condition was asso-
ciated with higher cost quintiles, with results reported as
unadjusted odds ratios.
For all variables, 95 % confidence intervals were pre-
sented. The magnitude of point estimates and the width
of confidence intervals were used primarily to interpret
results. Nominal P-values were calculated without ad-
justment for multiplicity; P < 0.05 was considered statis-
tically significant.
Results
In total, 251,591 patients were included in the final ana-
lysis. Figure 1 shows the inclusion/exclusion criteria, defi-
nitions, and sample size of patient cohorts. Baseline
demographic characteristics of patients at the time of
index hospitalization are summarized in Additional file 1:
Table S1. Compared with controls, pneumonia patients
were more likely to be older (mean age S. aureus:
60.5 years; P. aeruginosa: 62.8 years vs controls: 57.5 years)
and male (S. aureus: 59.3 %; P. aeruginosa: 61.5 % vs con-
trols: 56.3 %). Most patients in each cohort were covered
by a preferred-provider type health plan (68 %-70 %).
Costs
Table 1 presents a summary of the total and inpatient
costs for the pre-index, index, and post-index (30 and
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Table 1 Healthcare costs for ICU patients with S. aureus or P. aeruginosa pneumonia versus controls










(SD) (n = 1007)
Differencea P valuea Differenceb P valueb
(95 % CI) (95 % CI)
Pre-index costs,c $ (12 months)
Total all-cause costs 17,379 (38,923) 24,865 (55,676) 29,364 (65,771) 7,487 (6,024, 9,041) <.001 11,985 (9,436, 14,776) <.001
Inpatient hospitalization costs 5,985 (25,095) 10,389 (40,126) 11,885 (47,091) 4,405 (3,274, 5,674) <.001 5,900 (4,015, 8,140) <.001
Index hospitalization costs,c $
Total costs 33,851 (51,770) 146,978 (235,598) 213,104 (338,552) 100,216 (94,346, 106,360) <.001 159,361 (146,758, 172,856) <.001
Post-index costs,c $ (30 days)
Total all-cause costs 4,732 (18,044) 8,243 (23,838) 11,122 (42,503) 3,773 (3,236, 4,348) <.001 6,327 (5,285, 7,484) <.001
Inpatient hospitalization costs 2,610 (17,052) 4,836 (22,950) 7,447 (41,852) 2,710 (2,147, 3,343) <.001 5,139 (3,924, 6,590) <.001
Post-index costs,c $ (90 days)
Total all-cause costs 10,575 (27,653) 17,460 (39,286) 22,277 (54,113) 7,250 (6,231, 8,335) <.001 10,842 (9,014, 12,852) <.001
Inpatient hospitalization costs 4,913 (23,187) 9,281 (35,261) 13,527 (50,214) 4,731 (3,727, 5,860) <.001 8118 (6,110, 10,513) <.001
Index hospitalization + post-index costs (30 days),c $
Total all-cause costs 38,583 (57,402) 155,221 (240,527) 224,226 (346,331) 101,579 (95,681, 107,742) <.001 162,756 (150,118, 176,254) <.001
Inpatient hospitalization costs 36,461 (56,270) 151,813 (239,022) 220,552 (344,991) 102,287 (96,175, 108,687) <.001 163,862 (150,714, 177,947) <.001
CI confidence interval, ICU intensive care unit
aDifferences in means are from gamma regression model (link = log). Statistical comparisons are comparing Cohort 3 (pneumonia due to S. aureus) with Cohort 1 (no pneumonia, reference group); ie, Difference =mean
(Cohort 3) −mean (Cohort 1)
bDifferences in means are from gamma regression model (link = log). Statistical comparisons are comparing Cohort 4 (pneumonia due to P. aeruginosa) with Cohort 1 (no pneumonia, reference group); ie, Difference =mean
(Cohort 4) −mean (Cohort 1)
cCosts include $0 costs. All costs adjusted for calendar year, reported in 2012 dollars. All costs rounded to nearest dollar
All statistical models were controlled for the following variables: age (continuously), gender, health plan type, geographic region, and DCI comorbidity score. Models of index hospitalization costs and post-index costs
were also controlled for the analogous healthcare costs during the 12 month pre-index period. Additional covariates were selected separately for each outcome using a forward selection method. The following additional
covariates were considered for inclusion in the models: comorbid conditions (binary for each condition), prior healthcare utilization during the 12 month pre-index period (inpatient stays [0 vs 1+], emergency room visits














90 day) periods. Mean total costs for the index
hospitalization were approximately 4 and 6 times greater
in patients with S. aureus or P. aeruginosa pneumonia, re-
spectively, than in those in the control group, resulting in
incremental costs of > $100,000.
During the first 30 days after index hospitalization dis-
charge, patients in the S. aureus cohort incurred roughly
74 % higher mean costs than the control cohort ($8,243 vs
$4732), and the P. aeruginosa cohort incurred more than
double the mean cost compared with the control cohort.
A similar pattern persisted during the 90 days following
index hospitalization discharge.
During the index and 90-day post discharge periods
inpatient costs are the major contributor for the overall
costs in the S. aureus and P. aeruginosa cohorts and
controls (>95 % vs 87.3 %, respectively). Inpatient and
total costs were, respectively, $156,259 and $164,437
in the S. aureus pneumonia cohort and $226,631 and
$235,381 in the P. aeruginosa pneumonia cohort com-
pared with $38,765 and $44,427 for the control cohort
(Table 1).
Mortality within 90 days of discharge
Patients with pneumonia due to S. aureus or P. aeruginosa
experienced significantly (P < .001) higher rates of mortal-
ity during the index hospitalization and the 90-day follow
up period versus controls (Table 2). The rate of all-cause
mortality from the index hospitalization through the end
of the 90-day follow up period was also significantly
higher (P < .001) in these cohorts. The mortality rates
during the 90 days post-index period for patients who
survived the index hospitalization were both signifi-
cantly higher than the rate in controls (P < .001 for
both). Overall survival rates during the post-index
period (following index hospitalization discharge) were
significantly lower (P < .001) in the S. aureus and P.
aeruginosa cohorts compared with the control group.
Healthcare utilization
Pre-index healthcare utilization in the S. aureus and P.
aeruginosa cohorts was greater than in the control group.
Patients who acquired these pneumonias during the index
hospitalization had higher rates of inpatient hospitaliza-
tions and longer lengths of stay in the 12 months before
the index hospitalization versus controls (Additional file 1:
Table S3). The mean number of pre-index emergency
room, office and outpatient visits was also generally higher
among S. aureus and P. aeruginosa pneumonia patients
than in controls (Additional file 1: Table S3). The percent-
age of patients with ≥1 visit to a skilled nursing facility in
the pre-index period was much higher in both the S. aur-
eus and P. aeruginosa cohorts than in the control cohort
(P < .001). Antibiotic use was also significantly higher
(Additional file 1: Table S3).
Healthcare utilization during the index hospitalization
was higher among the S. aureus and P. aeruginosa cohorts
Table 2 All-cause mortality of ICU patients with S. aureus or P. aeruginosa pneumonia versus controls



















No. (%) of patients 6,188 (3.1) 363 (16.0) 203 (20.2) 5.99 (5.34, 6.72) <.001 7.97 (6.81, 9.31) <.001
Post-index mortality
No. (%) of patients 5,609 (2.8) 227 (10.0) 117 (11.6) 3.87 (3.37, 4.45) <.001 4.59 (3.78, 5.57) <.001
Mean (SD) time to deathc 32.8 (27.1) 25.5 (25.8) 28.1 (28.4) -7.30 (-10.51, -3.63) <.001 -4.69 (-9.44, 1.02) .10
Survival rate: 3.75 (3.28, 4.28) <.001 4.40 (3.66, 5.28) <.001
30 days (%) 98.5 93.4 92.9
90 days (%) 97.2 90.0 88.4
Index + post-index mortality
No. (%) of patients 11,797 (5.9) 590 (25.9) 320 (31.8) 5.63 (5.11, 6.19) <.001 7.49 (6.55, 8.56) <.001
Mean (SD) time to deathc 24.9 (28.3) 46.4 (47.6) 63.5 (59.3) 21.53 (17.39, 26.07) <.001 38.57 (31.08, 47.07) <.001
CI confidence interval, ICU intensive care unit
aOdds ratio (OR) from Chi-square test is used for categorical variables, negative binomial models are used to test for differences between means for count variables
(number of events and length of stay). Statistical comparisons are comparing Cohort 3 (pneumonia due to S. aureus) with Cohort 1 (no pneumonia, reference group);
ie, Difference = mean (Cohort 3) −mean (Cohort 1) and OR = Odds (Cohort 3)/Odds (Cohort 1)
bOdds ratio (OR) from Chi-square test is used for categorical variables, negative binomial models are used to test for differences between means for count variables
(number of events and length of stay). Statistical comparisons are comparing Cohort 4 (pneumonia due to P. aeruginosa) with Cohort 1 (no pneumonia, reference
group); i.e., Difference =mean (Cohort 4) −mean (Cohort 1) and OR = Odds (Cohort 4)/Odds (Cohort 1)
cIncluding only patients with mortality
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versus the control cohort. Patients with S. aureus or P.
aeruginosa pneumonia had significantly (P < .001) longer
overall mean hospital stays (37.9 and 55.4 days, respect-
ively) versus controls (7.2 days), ICU stays (6.9 and
14.8 days, respectively vs 1.1 days), and higher rates of
mechanical ventilation during the index hospitalization
(Table 3).
During the 30 day post discharge period, a significantly
(P > .001) greater proportion of the survivors represented
in the S. aureus and P. aeruginosa cohorts had inpatient
hospitalizations and ICU visits) (Table 4) and skilled
nursing facility visits (Additional file 1: Table S3) than
did survivors in the control group, whereas the proportion
of patients with office and outpatient visits were lower
(P < .001) in the S. aureus and P. aeruginosa cohorts
versus the control group (Additional file 1: Table S3). A
similar pattern in healthcare utilization was seen within
90 days after index discharge.
Survivors in the S. aureus and P. aeruginosa cohorts
were more likely than controls to have a repeat pneumo-
nia diagnosis during a subsequent hospital admission.
Within the S. aureus cohort, during the 30-day and 90-
day follow up period, respectively, re-hospitalization
that included a diagnosis of S. aureus pneumonia
accounted for 9.6 % and 10.0 % of inpatient admissions
and 21.4 % and 15.3 % of readmissions to the ICUs.
For the P. aeruginosa cohort, re-hospitalization that
included a diagnosis of P. aeruginosa pneumonia
accounted for 16.7 % and 20.0 % of inpatient admis-
sions, and 30.9 % and 30.9 % of ICU admissions during
these periods (Table 4, Table 5). Most readmissions
due to pneumonia during the follow up period
occurred during the first 30 days, particularly for the
patients with S. aureus pneumonia.
Comorbidities
The most common prespecified comorbidities identified
by coding during the 12-month pre-index period across
the 3 cohorts were hypertension, diabetes, coronary
heart disease, anemia, and chronic obstructive pulmon-
ary disease (Additional file 1: Table S4). Almost all
comorbidities were more prevalent in patients with S.
aureus or P. aeruginosa pneumonia than in controls.
The mean DCI score 2.3 for the S. aureus and 2.5 for
the P. aeruginosa cohort; both were significantly higher
than in the control cohort (mean DCI = 1.7).
Additional file 1: Table S5 displays the prevalence of
comorbidities within the cost quintiles for each cohort.
Most of the comorbid conditions were not associated
with significantly higher costs within the S. aureus and
P. aeruginosa cohorts during the index hospitalization
(ie, the odds ratio of the likelihood of appearing in a
high cost quintile in the presence of the comorbidity
versus the absence of the comorbidity was not signifi-
cantly greater than 1; Table 4). Hepatitis B infection and
solid organ transplant were associated with higher costs
within the S. aureus cohort only, but the P values were
of marginal significance given the small sample sizes.
Nearly half of the comorbid conditions, including 4
cardiovascular conditions, were associated with signifi-
cantly lower index hospitalization costs for either one or
both of the S. aureus and P. aeruginosa cohorts (Table 6).
Congestive heart failure, peripheral artery disease, and
chronic obstructive pulmonary disease were associated
with significantly lower costs in both the S. aureus and
P. aeruginosa cohorts. Additionally, myocardial infarc-
tion, other coronary heart disease, and dementia were
associated with lower costs in the S. aureus cohort;
asthma, immunosuppression, human immunodeficiency
Table 3 Healthcare resource utilization for ICU patients with S. aureus or P. aeruginosa pneumonia versus controls during index
hospitalization
Cohorts of interest S. aureus pneumonia vs No
pneumonia









Odds Ratio/Differencea P Valuea Odds Ratio/Differenceb P Valueb
(95 % CI) (95 % CI)
N = 201,394 N = 2275 N = 1007
Mean (SD) length of hospital
stay per patient
7.2 (9.6) 37.9 (39.4) 55.4 (54.9) 30.69 (29.41, 32.00) <.001 48.18 (45.43, 51.08) <.001
Mean (SD) length of ICU/CCU
stay per patient
1.1 (2.1) 6.9 (21.1) 14.8 (36.6) 5.75 (5.59, 5.91) <.001 13.63 (13.21, 14.06) <.001
No. (%) of patients with
mechanical ventilation
14,960 (7.4) 1,425 (62.6) 627 (62.3) 20.89 (19.16, 22.78) <.001 20.56 (18.08, 23.38) <.001
CI confidence interval, ICU intensive care unit
aOdds ratio (OR) from Chi-square test is used for categorical variables, negative binomial models are used to test for differences between means for count variables
(number of events and length of stay). Statistical comparisons are comparing Cohort 3 (pneumonia due to S. aureus) with Cohort 1 (no pneumonia, reference group);
ie, Difference = mean (Cohort 3) −mean (Cohort 1) and OR = Odds (Cohort 3)/Odds (Cohort 1)
bOdds ratio (OR) from Chi-square test is used for categorical variables, negative binomial models are used to test for differences between means for count variables
(number of events and length of stay). Statistical comparisons are comparing Cohort 4 (pneumonia due to P. aeruginosa) to Cohort 1 (no pneumonia, reference group);
ie, Difference =mean (Cohort 4) – mean (Cohort 1) and OR = Odds (Cohort 4)/Odds (Cohort 1)
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Table 4 Healthcare resource utilization for ICU patients with S. aureus or P. aeruginosa pneumonia versus controls through 30 days post index hospitalization
Cohorts of interest S. aureus pneumonia vs No
pneumonia








Odds Ratio/Differencea P Valuea Odds Ratio/Differenceb P
Valueb(95 % CI) (95 % CI)
No. of patients completing 30 day follow up periodc n = 192,204 n = 1762 n = 732
All-cause inpatient hospitalizations
No. (%) of patients with ≥1 event 29,451 (15.3) 480 (27.2) 228 (31.1) 2.07 (1.86, 2.30) <.001 2.50 (2.14, 2.93) <.001
Mean (SD) events per patient with at least 1 event 1.3 (0.7) 1.6 (1.3) 1.5 (1.2) 0.30 (0.19, 0.42) <.001 0.24 (0.09, 0.41) .002
Mean (SD) length of stay per patient with at least 1 event 5.4 (5.5) 8.4 (7.3) 9.5 (7.7) 3.02 (2.38, 3.71) <.001 4.15 (3.13, 5.29) <.001
No. (%) of patients with ≥1 hospitalization for pneumonia due to S. aureus 52 (0.03) 46 (2.6) 13 (1.8) 99.06 (66.43, 147.71) <.001 66.81 (36.22, 123.23) <.001
No. (%) of patients with ≥1 hospitalization for pneumonia due to P. aeruginosa 31 (0.02) 16 (0.9) 38 (5.2) 56.81 (31.02, 104.05) <.001 339.43 (210.00, 548.64) <.001
ICU stays
No. (%) of patients with ≥1 event 5027 (2.6) 84 (4.8) 55 (7.5) 1.86 (1.50, 2.33) <.001 3.03 (2.30, 3.99) <.001
Mean (SD) events per patient with at least 1 event 1.0 (0.2) 1.0 (0.1) 1.0 (0.0) -0.01 (-0.21, 0.23) .89 −0.03 (−0.26, 0.28) .85
Mean (SD) length of stay per patient with at least 1 event 1.3 (1.6) 1.4 (3.0) 1.3 (1.2) 0.10 (-0.14, 0.40) .44 0.02 (−0.27, 0.38) .91
No. (%) of patients with ≥1 hospitalization for pneumonia due to S. aureus 34 (0.02) 18 (1.0) 7 (1.0) 58.34 (32.88, 103.49) <.001 54.57 (24.11, 123.50) <.001
No. (%) of patients with ≥1 hospitalization for pneumonia due to P. aeruginosa 18 (0.01) 8 (0.5) 17 (2.3) 48.72 (21.16, 112.18) <.001 253.83 (130.29, 494.51) <.001
CI confidence interval, ICU intensive care unit
aOdds ratio (OR) from Chi-square test is used for categorical variables, negative binomial models are used to test for differences between means for count variables (number of events and length of stay). Statistical
comparisons are comparing Cohort 3 (pneumonia due to S. aureus) with Cohort 1 (no pneumonia, reference group); ie, Difference =mean (Cohort 3) −mean (Cohort 1) and OR = Odds (Cohort 3)/Odds (Cohort 1)
bOdds ratio (OR) from Chi-square test is used for categorical variables, negative binomial models are used to test for differences between means for count variables (number of events and length of stay). Statistical
comparisons are comparing Cohort 4 (pneumonia due to P. aeruginosa) to Cohort 1 (no pneumonia, reference group); ie, Difference =mean (Cohort 4) – mean (Cohort 1) and OR = Odds (Cohort 4)/Odds (Cohort 1)














virus infection, and Hepatitis B infection were associated
with lower costs in the P. aeruginosa cohort. However,
the results for immunosuppression, human immunodefi-
ciency virus, and hepatitis B should be interpreted with
caution due to the small sample sizes (Additional file 1:
Table S4).
An exploratory analysis of congestive heart failure was
performed that stratified patients by age and mortality
(Additional file 1: Table S6) to control for potential cor-
relations between comorbidities and patient character-
istics and outcomes (Medicare eligibility and death)
that may result in lower hospitalization costs. The
results showed odds ratios <1 despite these additional
adjustments in the models. Similar results were found
in exploratory analyses of other pre-specified conditions
with odds ratios <1.
Discussion
This is the largest US claims database study of healthcare
costs and outcomes for ICU patients with a diagnosis
of S. aureus or P. aeruginosa pneumonia. Our findings
highlight the comprehensive economic consequences
attributed to S. aureus and P. aeruginosa pneumonia
and can permit policy makers, payers, and healthcare
providers to assess the effect of prevention or thera-
peutic efforts on the cost and morbidity of these ICU
infections.
In our study, ICU patients with pneumonia had sub-
stantially higher healthcare costs during the index
admission: > $213,000 for P. aeruginosa pneumonia
and > $146,000 for with S. aureus pneumonia ver-
sus >$33,000 for patients without pneumonia. Increased
utilization continued after index hospitalization discharge,
Table 5 Healthcare resource utilization for ICU patients with S. aureus or P. aeruginosa pneumonia versus controls through 90 days
post index hospitalization
Cohorts of interest S. aureus pneumonia vs No
pneumonia









Odds Ratio/Differencea P Valuea Odds Ratio/Differenceb P Valueb
(95 % CI) (95 % CI)
No. of patients completing 90 day
follow up periodc
n = 189,597 n = 1685 n = 687
All-cause inpatient hospitalizations
No. (%) of patients with ≥1 event 44,246 (23.3) 641 (38.0) 295 (42.9) 2.02 (1.83, 2.23) <.001 2.48 (2.13, 2.88) <.001
Mean (SD) events per patient with
at least 1 event
1.5 (1.0) 1.9 (2.0) 2.0 (1.9) 0.45 (0.34, 0.56) <.001 0.46 (0.31, 0.63) <.001
Mean (SD) length of stay per patient
with at least 1 event
7.8 (10.7) 14.7 (18.4) 17.5 (19.8) 6.96 (5.82, 8.19) <.001 9.79 (7.85. 11.97) <.001
No. (%) of patients with ≥1
hospitalization for pneumonia
due to S. aureus
112 (0.06) 64 (3.8) 20 (2.9) 66.80 (48.95, 91.17) <.001 50.74 (31.34, 82.14) <.001
No. (%) of patients with ≥1
hospitalization for pneumonia
due to P. aeruginosa
63 (0.03) 29 (1.7) 59 (8.6) 52.69 (33.85, 82.01) <.001 282.61(196.46, 406.55) <.001
ICU stays
No. (%) of patients with ≥1 event 9,399 (5.0) 163 (9.7) 97 (14.1) 2.05 (1.75, 2.42) <.001 3.15 (2.54, 3.91) <.001
Mean (SD) events per patients with
at least 1 event
1.1 (0.4) 1.1 (0.3) 1.2 (0.5) -0.02 (-0.17, 0.15) .80 0.10 (-0.10, 0.34) .37
Mean (SD) length of stay per patients
with at least 1 event
1.6 (3.6) 3.5 (10.1) 1.9 (3.6) 1.92 (1.46, 2.44) <.001 0.34 (-0.01, 0.77) .06
No. (%) of patients with ≥1
hospitalization for pneumonia
due to S. aureus
66 (0.03) 25 (1.5) 9 (1.3) 43.25 (27.23, 68.70) <.001 38.13 (18.93, 76.81) <.001
No. (%) of patients with ≥1
hospitalization for pneumonia
due to P. aeruginosa
32 (0.02) 17 (1.0) 30 (4.4) 60.38 (33.46, 108.94) <.001 270.47 (163.40, 447.69) <.001
CI confidence interval, ICU intensive care unit
aOdds ratio (OR) from Chi-square test is used for categorical variables, negative binomial models are used to test for differences between means for count
variables (number of events and length of stay). Statistical comparisons are comparing Cohort 3 (pneumonia due to S. aureus) with Cohort 1 (no pneumonia,
reference group); ie, Difference =mean (Cohort 3) −mean (Cohort 1) and OR =Odds (Cohort 3)/Odds (Cohort 1)
bOdds ratio (OR) from Chi-square test is used for categorical variables, negative binomial models are used to test for differences between means for count
variables (number of events and length of stay). Statistical comparisons are comparing Cohort 4 (pneumonia due to P. aeruginosa) to Cohort 1 (no pneumonia,
reference group); ie, Difference = mean (Cohort 4) – mean (Cohort 1) and OR = Odds (Cohort 4)/Odds (Cohort 1)
cPost-index utilization results include only patients who survived to the end of the 30 or 90 day post-discharge period
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with total healthcare costs through 90 days post discharge
of > $17,000 for patients with S. aureus pneumonia and >
$22,000 for patients with P. aeruginosa pneumonia ver-
sus > $10,000 for patients without pneumonia. Patients
with S. aureus or P. aeruginosa pneumonia had estimated
incremental index hospitalization costs of $100,000-
$160,000 and total healthcare costs of $107,000-$167,000
versus ICU patients without pneumonia. In previous stud-
ies of the general US inpatient population, the mean cost
of hospital care in patients with hospital-acquired pneu-
monia was $72,000 versus $46,400 to $65,292 for patients
without pneumonia [2, 22]. A German study reported an
excess mean cost of DM29,610 (equivalent to $16,824 in
2001) for hospital-acquired pneumonia in ICU patients
compared with ICU patients without pneumonia [23].
Previous US studies in VAP patients estimated that the
incremental costs were $39,000 to $100,000 for VAP
patients versus ICU patients without VAP, which is
consistent with our observations [24, 25].
Our findings showed that S. aureus pneumonia and,
especially, P. aeruginosa pneumonia had prolonged hospi-
talizations (>48 days longer for P. aeruginosa and >30 days
longer for S. aureus) and ICU stays (approximately 15 days
for those with P. aeruginosa pneumonia, 7 days for those
with S. aureus pneumonia, compared with 1 day for those
without pneumonia). Mortality was also substantially
higher: >20 % of those with P. aeruginosa pneumonia and
16 % of those with S. aureus pneumonia died during the
Table 6 Impact of comorbidities on index hospitalization costs for ICU patients with S. aureus or P. aeruginosa pneumonia
Comorbidity S. aureus pneumonia P. aeruginosa pneumonia
Odds Ratioa P Valuea Odds Ratioa P Valuea
(95 % CI) (95 % CI)
Diabetes 1.10 (0.93, 1.31) .27 1.12 (0.86, 1.46) .40
Myocardial infarction 0.58 (0.42, 0.82) .002 1.14 (0.71, 1.82) .59
Congestive heart failure 0.74 (0.60, 0.92) .007 0.72 (0.52, 0.99) .04
Peripheral artery disease 0.69 (0.54, 0.88) .003 0.70 (0.49, 0.99) .04
Stroke, TIA, cerebrovascular disease 0.81 (0.65, 1.01) .06 1.17 (0.83, 1.65) .37
Hypertension 0.96 (0.80, 1.14) .62 1.16 (0.88, 1.52) .29
Other coronary heart disease 0.80 (0.66, 0.97) .03 0.94 (0.71, 1.24) .65
Anemia 0.88 (0.72, 1.07) .20 1.12 (0.84, 1.50) .44
COPD 0.68 (0.57, 0.82) <.001 0.46 (0.35, 0.60) <.001
Asthma 0.95 (0.76, 1.20) .67 0.60 (0.43, 0.84) .003
Renal disease 0.90 (0.70, 1.15) .38 1.06 (0.73, 1.52) .77
Chronic liver disease 1.17 (0.87, 1.58) .29 0.85 (0.54, 1.33) .47
Neutropenia 1.53 (0.91, 2.58) .11 0.59 (0.29, 1.19) .14
Immunosuppression 1.05 (0.51, 2.16) .89 0.39 (0.16, 0.96) .04
HIV 1.00 (0.34, 2.90) .996 0.27 (0.08, 0.88) .03
Hepatitis B 4.77 (1.05, 21.72) .04 0.04 (0.00, 0.74) .03
Hepatitis C 0.96 (0.45, 2.05) .92 0.57 (0.19, 1.70) .31
Obesity/Overweight 1.03 (0.78, 1.36) .86 1.15 (0.76, 1.75) .50
Dementia 0.55 (0.35, 0.86) .009 1.76 (0.75, 4.15) .20
Dialysis 0.62 (0.33, 1.15) .13 1.21 (0.53, 2.78) .65
Leukemia 0.61 (0.27, 1.35) .22 1.03 (0.43, 2.47) .95
Lymphoma 1.60 (0.91, 2.82) .11 1.21 (0.56, 2.58) .63
Cancer other than leukemia or lymphoma 0.88 (0.58, 1.34) .56 0.93 (0.51, 1.70) .82
Bone marrow transplant 0.89 (0.15, 5.30) .89 0.61 (0.11, 3.43) .58
Solid organ transplant 1.90 (1.02, 3.53) .04 1.31 (0.66, 2.57) .44
CI confidence interval, COPD chronic obstructive pulmonary disease, HIV human immunodeficiency virus, ICU intensive care unit, TIA transient ischemic attack
aOrdinal logistic regression odds ratio (OR) is used to test the association between the presence of each comorbidity and index hospitalization cost quintiles, ie,
OR = Odds (patient with comorbidity in high cost quintile)/ Odds (patient without comorbidity in high cost quintile). OR >1 means presence of the comorbidity
leads to greater costs, whereas OR <1 means presence of the comorbidity leads to lower costs
All statistical models were controlled for the following variables: age (continuously), gender, health plan type, geographic region, prior inpatient hospitalization
costs during the 12 month pre-index period, prior healthcare utilization during the 12 month pre-index period (inpatient stays [0 vs 1+], emergency room visits
[0 vs 1+], outpatient and office visits [continuous]), and prior antibiotic use during the 12 month pre-index period (0 vs. 1+)
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index hospitalization versus approximately 3 % of control
patients, and this trend continued after discharge. The
findings of longer ICU lengths of stay and longer hospital
lengths of stay are consistent with prior studies [2, 22–24].
We found significantly higher rehospitalization rates in
patients with S. aureus and P. aeruginosa pneumonia ver-
sus controls. Readmission after discharge can be costly
and problematic for the patient, hospitals, and payers. It
was estimated that hospital readmissions cost Medicare
$17.5 billion alone annually in the United States [26].
Financial penalties are now incurred for hospitals with ex-
cess 30-day readmission in the United States. Therefore,
preventing S. aureus and P. aeruginosa pneumonias could
reduce the substantial costs of and healthcare utilization
associated with rehospitalization in patients with these in-
fections, resulting in benefits for patients, payers, and
healthcare providers.
ICU patients with S. aureus or P. aeruginosa pneumo-
nia were older, more likely to be male, and in poorer
general health than those who did not have pneumonia.
Most patients (>62 %) were mechanically ventilated; this
is likely to be an underestimate, because mechanical
ventilation is not uniformly recorded in a claims data-
base. These mechanically-ventilated patients represent
both those with VAP and those with non-ventilator-
associated pneumonia that required ventilator support.
The demographic skew to older, male patients has been
previously reported in patients with VAP; however, in
some studies, patients with VAP were younger than were
those without VAP, which may reflect the contribution
of trauma patients to the demographics [24, 27].
The findings regarding the impact of comorbid condi-
tions on the hospitalization costs of S. aureus or P. aeru-
ginosa pneumonia are unique to the present study. The
results indicate that while the presence of comorbid con-
ditions increases the likelihood that an ICU patient will
develop S. aureus or P. aeruginosa pneumonia, the
presence of comorbidities does not inflate the costs of
hospital care for the patient. A number of comorbid
conditions were associated with lower, rather than
higher, hospitalization costs for S. aureus or P. aeruginosa
pneumonia. Exploratory analysis demonstrated that the
lower costs are not solely due to higher mortality or
higher rates of Medicare coverage among patients with
the comorbid conditions. It is unknown why these inverse
associations exist.
Claims data represent an excellent starting point for
the examination of health outcomes, treatment patterns,
healthcare resource utilization, and costs. However, our
analyses have several limitations. This study was retro-
spective and used ICD-9 codes to include and exclude
subjects from specific cohorts, a method associated with
known limitations [28]. Because the included codes were
selected to be specific rather than sensitive, the numbers
of patients identified cannot be used to establish inci-
dence rates. It is possible that other pneumonia codes,
including the code for VAP, included some episodes of
P. aeruginosa or S. aureus pneumonia. Comorbidities
were identified by their presence in coded diagnoses in
the 12 months before the index hospitalization; this ap-
proach is likely very sensitive and intended to capture
as many comorbid conditions as possible but likely has
limited specificity due to the criteria of only requiring
one diagnosis code. Diagnoses made during the index
hospitalization were not included, because the goal of
the current analysis was to assess the information available
to clinicians upon admission; this may have contributed to
underdiagnosis of co-morbid conditions. Future studies
may want to examine the association between costs and
both pre-existing and new comorbidities to explore the
impact of how comorbidities are defined. Additionally,
separating patients into those hospitalized for a life-
threatening pneumonia from those who acquired
pneumonia in the hospital would be useful in assessing
prevention strategies, however claims database analyses
do not permit separation into these groups. Furthermore,
the database only included patients who had commercial
healthcare insurance and may not be representative of the
overall US population; patients covered solely by Medicare
or Medicaid were excluded. However, the claims database
comprised patients aged ≥18 years in a managed care set-
ting and included substantial numbers of subjects of
Medicare age; moreover, results may be generalizable to
similar patient groups. Despite these limitations, our re-
sults provide accurate assessments of resource utilizations
and costs in these patients due to appropriate adjustments
in the statistical models.
Conclusion
Overall, these results indicate that S. aureus and P. aeru-
ginosa pneumonia in ICU patients impose substantial
costs, healthcare utilization, and burden for patients
[29]. The demand for critical care services is increasing
as the aging US population requires a greater level of
critical and end of life care, and emergency departments
are accelerating their rates of ICU admissions [30].
These services are costly; in 2005, ICUs in the United
States accounted for 23.2 million patient days and $81.7
billion in expenditures. Our results highlight the eco-
nomic importance of effective interventions to reduce
the burden of S. aureus and P. aeruginosa pneumonia in
ICUs in the United States.
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Pre- and post-index healthcare resource utilization for ICU patients
with S. aureus or P. aeruginosa pneumonia versus controls. Table S4.
Comorbidities of ICU patients with S. aureus and P. aeruginosa pneumonia
versus controls. Table S5. Prevalence of comorbid conditions by quintile of
index hospitalization cost for ICU patients with S. aureus or P. aeruginosa
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of congestive heart failure on index hospitalization costs in ICU patients
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